BACKGROUND:The current study was conducted to develop a pretreatment prognostic model for patients with unresectable and/or metastatic urothelial cancer who were treated with first-line, cisplatin-based chemotherapy. METHODS: Individual data were pooled from 399 patients who were enrolled on 8 phase 2 and 3 trials evaluating cisplatin-based, first-line chemotherapy in patients with metastatic urothelial carcinoma. Variables selected for inclusion in the model were combined in a Cox proportional hazards model to produce a points-based nomogram with which to predict the median, 1-year, 2-year, and 5-year survival. The nomogram was validated externally using data from a randomized trial of the combination of methotrexate, vinblastine, doxorubicin plus cisplatin versus docetaxel plus cisplatin. RESULTS: The median survival of the development cohort was 13.8 months (95% confidence interval, 12.1 months-16.0 months); 68.2% of the patients had died at the time of last follow-up. On multivariable analysis, the number of visceral metastatic sites, Eastern Cooperative Oncology Group performance status, and leukocyte count were each found to be associated with overall survival (P <.05), whereas the site of the primary tumor and the presence of lymph node metastases were not. All 5 variables were included in the nomogram. When subjected to internal validation, the nomogram achieved a bootstrap-corrected concordance index of 0.626. When applied to the external validation cohort, the nomogram achieved a concordance index of 0.634. Calibration plots suggested that the nomogram was well calibrated for all predictions. CONCLUSIONS: Based on routinely measured pretreatment variables, a nomogram was constructed that predicts survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. This model may be useful in patient counseling and clinical trial design. Cancer 2013;119:3012-9. V C 2013 American Cancer Society.KEYWORDS: urothelial cancer; bladder cancer; prognosis; metastatic; chemotherapy; cisplatin.
INTRODUCTIONContemporary cisplatin-based combination chemotherapy regimens achieve objective responses in approximately 50&percnt to 60% of patients with metastatic urothelial cancer.1,2 Although response durations are generally short, and the median overall survival of patients with unresectable and/or metastatic urothelial cancer is only approximately 14 months, significant heterogeneity exists with regard to patient outcomes.2 Long-term follow-up of clinical trials has demonstrated that approximately 10% to 20% of patients are alive at 5 years.1,3 The ability to predict individual patient outcomes has clear implications with regard to both patient counseling and patient stratification on clinical trials.Prognostic models have previously been developed for chemotherapy-naive patients with unresectable and/or metastatic urothelial cancer. In 1998, Bajorin et al identified Karnofsky performance status and the presence of visceral metastases as independent predictors ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.